The Peter Dukor Memorial Symposium
IgE-Mediated Allergen Presentation via Fc Epsilon Rl on Antigen-Presenting CellsStingl G. · Maurer D.
Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, University of Vienna Medical School, Vienna, Austria
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
In atopic individuals, cutaneous antigen-presenting cells (APC), i.e. Langerhans’ cells (LC) and dermal dendritic cells (DDC), frequently display anti-IgE reactivity. While earlier observations suggested that this phenomenon results from the binding of (complexed) IgE to the low affinity IgE receptor (FcεRII/CD23), recent evidence exists that LC and DDC, as well as peripheral blood dendritic cells and monocytes from atopic individuals, can bind monomeric IgE via the high-affinity receptor for IgE (FcεRI). We have now found that FcεRI, both quantitatively and qualitatively, is the pivotal serum IgE-binding structure on APC of atopic individuals, that FcεRI on APC functions as allergen-focusing molecule and that allergens are more efficiently taken up, processed and presented to T cells following targeting to APC via FcεRI compared to allergen binding to APC in the conventional manner. In vivo, FcεRI-IgE-dependent allergen presentation may critically lower atopic individuals’ threshold to mount allergen-specific T cell responses. This would result in the perpetuation of allergen-specific IgE production (type I reactions) and perhaps even in the occurrence of T-cell-mediated delayed-type hypersensitivity reactions in allergen-exposed tissues.
© 1997 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.